-
PPT: A Causal Lens on ERα in LUAD
2026-09-15
PPT (Propyl Pyrazole Triol) provides a selective way to test whether ERα activity contributes to female lung adenocarcinoma biology. This article develops a causal assay framework that connects the FOXM1–miR-204-5p–ERα hypothesis to receptor-dependent experimental decisions.
-
Midecamycin Workflows for Gram-Positive Assays
2026-09-15
Midecamycin is an acetoxy-substituted macrolide antibiotic for resolving Gram-positive susceptibility, macrolide cross-resistance, and glycosylation-related loss of activity in controlled laboratory assays. This workflow-focused guide covers stock preparation, MIC and MBC testing, comparative interpretation, and troubleshooting for reproducible microbiology research.
-
HRD1-SEL1L Control of Stress Granule Homeostasis
2026-09-14
The 2024 iScience study identifies the HRD1-SEL1L ubiquitin ligase as a stressor-selective regulator of heat shock-induced stress granule homeostasis. Its experiments connect ER quality control to cytosolic stress responses through a BiP-PERK-eIF2α pathway and show that distinct unfolded protein response branches do not contribute equivalently.
-
From HMGB1 Discovery to Spatial Validation
2026-09-14
Quantitative proteomics has positioned HMGB1 as a promising candidate for early diabetic nephropathy monitoring, but translational confidence depends on orthogonal validation. This article explains how a Cy3-conjugated secondary antibody can connect serum biomarker discovery with spatially resolved immunofluorescence, immunohistochemistry, and immunocytochemistry workflows while preserving appropriate scientific limitations.
-
tRF16–ALKBH5–NFKBIA Axis in Osteoarthritis
2026-09-13
A 2025 Communications Biology study identifies tRF16 as an overexpressed tRNA-derived fragment that promotes osteoarthritis through an ALKBH5–NFKBIA–NF-κB regulatory axis. Its combination of human tissue profiling, rat modeling, and IL-1β-treated chondrocytes provides a mechanistic framework for connecting noncoding RNA, m6A-dependent RNA regulation, inflammation, and cartilage degeneration.
-
Liproxstatin-1 HCl: A Mechanistic Assay Guide
2026-09-12
Liproxstatin-1 HCl is a selective ferroptosis inhibitor that helps distinguish lipid-peroxidation-driven death from apoptosis and nonspecific oxidative injury. This guide connects assay design with mitochondrial calcium–GPX4 biology to improve mechanistic interpretation in cellular and organ-injury models.
-
Iptacopan (LNP023) for Complement Assays
2026-09-12
Iptacopan (LNP023) is a selective, reversible factor B inhibitor for dissecting alternative-pathway amplification in serum, red-cell, and disease-model workflows. Its proximal mechanism supports complement-mediated hemolysis assays, C3 deposition studies, and translational experiments that connect molecular inhibition with PNH-relevant outcomes.
-
Streptavidin-Cy3 for Spatial NPC Mechanisms
2026-09-11
Discover how Streptavidin-Cy3 converts biotinylated antibodies and nucleic acid probes into spatial evidence for nasopharyngeal carcinoma research. This article connects the seRNA-NPCm/NPM1/c-Myc/NDRG1 mechanism with practical IHC, ISH, immunofluorescence, and flow cytometry assay design.
-
KPT330 and Cas9 mRNA Export in Precision Editing
2026-09-11
The reference study identifies selective inhibitors of nuclear export, particularly KPT330, as indirect modulators of Cas9, base-editor, and prime-editor activity. By regulating Cas9 mRNA export rather than directly blocking the nuclease, this strategy improved editing specificity in human cells while introducing a distinct way to control the timing and dose of CRISPR activity.
-
Lumiracoxib: Selective COX-2 Research Guide
2026-09-10
Lumiracoxib is a selective COX-2 inhibitor for research on prostaglandin synthesis inhibition, inflammation, and tissue-repair signaling. Supplier specifications and a peer-reviewed muscle-injury study indicate that its biological effects depend on assay selectivity, exposure timing, and the measured vascular endpoint.
-
Developmental SSRI Exposure and Motivational Deficits
2026-09-10
A 2026 Columbia University dissertation shows that developmental SSRI exposure produces persistent, motivation-specific reward deficits in adolescent and adult mice. Progressive-ratio behavior improved after mu opioid receptor antagonism or nucleus accumbens MOR knockdown, identifying a circuit-level intervention distinct from subsequent SSRI treatment.
-
Tunicamycin in CVA: ER Stress and NLRP3
2026-09-09
The 2019 reference study identified endoplasmic reticulum stress as a mechanistic link between pulmonary dysfunction and NLRP3 inflammasome activation in cough variant asthma. Tunicamycin was used as a pharmacological stress challenge to test whether Suhuang antitussive capsule protected the lung by suppressing this pathway.
-
Epoxomicin Workflows for Proteasome Research
2026-09-09
Epoxomicin is a selective, irreversible proteasome inhibitor for connecting proteasome activity with protein turnover, inflammatory signaling, and viral pathogenesis. This workflow-focused guide shows how to prepare, dose, validate, and troubleshoot Epoxomicin in enzyme, cell-based, and RIPK3 degradation assays.
-
Lypressin Acetate: From Receptor Biology to Translation
2026-09-08
Lypressin acetate, also known as lysine vasopressin acetate, links vasopressin receptor pharmacology with translational research in diabetes insipidus, vasoconstriction, hemostasis, and exploratory SARS-CoV-2 RdRp studies. This article outlines how researchers can convert its receptor activity and peptide-handling requirements into disciplined experimental and strategic decisions.
-
IPR-803: Reliable uPAR Inhibition Workflows
2026-09-08
This scenario-driven guide explains how IPR-803, SKU BA8331, can support interpretable uPAR–uPA studies across viability, invasion, angiogenesis, and metastasis workflows. It separates biochemical potency from cellular dosing, highlights model-dependent readouts, and provides practical selection and handling guidance for laboratory teams.